Patient Journey

Top 14 Digital Health companies in the world by market cap. On average, the market cap is $4B. Stock performance was -50% over the past year. Street is still bullish with on average 77% higher target price. $TDOC, $GDRX, $OSH, $ONEM, $MPLN, $BBLN, $OM, $CLOV, $ACCD, $SHCR, $AMWL, $HIMS, $GOCO, $PEAR

Dear wonderful patients and followers, We would like to start a fundraise to help support our work on the technology development and research. Any small contribution will go a long ways!

Top 14 Digital Health companies in the world by market cap. On average, the market cap is $4B. Stock performance was -50% over the past year. Street is still bullish with on average 77% higher target price. $TDOC, $GDRX, $OSH, $ONEM, $MPLN, $BBLN, $OM, $CLOV, $ACCD, $SHCR, $AMWL, $HIMS, $GOCO, $PEAR

We have expanded into research on public digital health companies. Please see a summary on Pear Therapeutics below: Industry Summary - 1. There is a growing burden of chronic disease ... 2. There has been a large transition to telemedicine 3. There is a current shortage in providers 4. Technology has the ability to reach many Qualitative Summary on Pear - 1. Pear is the leader in PDT with 3 FDA-authorized and deep and broad pipeline 2. Pear has an established Scientific Steering Committee (SSC) which considers unsolicited research proposals by members of the medical and scientific community 3. Currently has three commercial products: Somryst, reSet & reSet-O, and pear connect Quantitative - 1. Revenue forecasted to be $4M, $22M and $125M in 2021E, 2022E, 2023E, respectively 2. Pear’s implied value at YE 2022- $3,147 (in millions) 3. Margin of safety for new investors - 9.61x EV / 2023E Revenue 4. Raised >$250M of capital from Softbank, Temasek, a leading IDN, Novartis, 5am Ventures, Jazz Ventures, Arboretum and more 5. reSET: only product FDA authorized to treat addiction to alcohol, cannabis, cocaine, and stimulants Total addressable market: $5B+ 6. reSET-O: only FDA authorized software product proven to help patients with opioid use disorder stay in outpatient treatment longer Total addressable market: $1B+ 7. Somryst: only FDA authorized drug-free and guideline recommended treatment for chronic insomnia Total addressable market: $5B+ #Novartis #FDA #digitaltherapeutics

We have created a new education video on the breast cancer drug Ibrance. Ibrance is one of the blockbuster drugs from Pfizer. We hope the education video is useful for the patient and care giver community. Please leave us any feedback. We would appreciate if you could like, share, and donate to our cause. We will continue to invest in this program.

Hi everyone, we have exciting updates to share with you. In order to fund these initiatives, we need your support. Please help us by supporting us through Amazon Smile.

We have expanded into research on public digital health companies. Please see a summary on Pear Therapeutics below: Industry Summary - 1. There is a growing burden of chronic disease ... 2. There has been a large transition to telemedicine 3. There is a current shortage in providers 4. Technology has the ability to reach many Qualitative Summary on Pear - 1. Pear is the leader in PDT with 3 FDA-authorized and deep and broad pipeline 2. Pear has an established Scientific Steering Committee (SSC) which considers unsolicited research proposals by members of the medical and scientific community 3. Currently has three commercial products: Somryst, reSet & reSet-O, and pear connect Quantitative - 1. Revenue forecasted to be $4M, $22M and $125M in 2021E, 2022E, 2023E, respectively 2. Pear’s implied value at YE 2022- $3,147 (in millions) 3. Margin of safety for new investors - 9.61x EV / 2023E Revenue 4. Raised >$250M of capital from Softbank, Temasek, a leading IDN, Novartis, 5am Ventures, Jazz Ventures, Arboretum and more 5. reSET: only product FDA authorized to treat addiction to alcohol, cannabis, cocaine, and stimulants Total addressable market: $5B+ 6. reSET-O: only FDA authorized software product proven to help patients with opioid use disorder stay in outpatient treatment longer Total addressable market: $1B+ 7. Somryst: only FDA authorized drug-free and guideline recommended treatment for chronic insomnia Total addressable market: $5B+ #Novartis #FDA #digitaltherapeutics

Information on breast cancer is scattered everywhere, but it is rarely ever applicable. With OpenPHR, learn from a journey that's similar to yours and make more informed decisions!